Lite Strategy Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lite Strategy Inc 's ROA in the third quarter of 2026?
Lite Strategy Inc recorded a cumulative net loss of $-61 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -89.36%.

However, within the Healthcare sector 711 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4214, from total ROA ranking in the second quarter of 2025 at 4769.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter	(Mar 31 2025) III. Quarter
Y / Y Total Assets Change	178.11 %	240.11 %	308.06 %	-56.51 %	-70.84 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-61	-40	-12	-16	-32
Return On Assets (TTM)	-89.36 %	-67.5 %	-26.21 %	-69.93 %	-110.17 %
LITS's Total Ranking	# 4214	# 4769	# 3682	# 4269	# 4567
Total Assets (TTM) in million	58	83	113	18	21
Seq. Total Assets Change	-30.32 %	-26.76 %	519.28 %	-12 %	-14.79 %
Seq. Net Income Change	-	-	-	-	-

LITS's 5 Years Annual ROA >> Back to LITS Management Effectiveness >> Compare LITS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 325
Sector	# 712
Overall	# 4175

Return On Assets Statistics
High	Average	Low
32.68 %	-41.01 %	-174.09 %
(Sep 30 2023)		(Sep 30 2012)

Financial Statements
Lite Strategy Inc 's Assets	$ 58 million	LITS's Balance sheet
Lite Strategy Inc 's Income	$ -24 million	Quarterly LITS's Income Statement
LITS's Income by Division		See LITS's Income by Division

Annual Return On Assets	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021
Y / Y Total Assets Change	-55.81 %	-65.75 %	-25.45 %	-2.12 %	-16.24 %
Total Assets in million	18	41	121	162	166
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-16	18	-32	-54	-41
Annual Return On Assets	-87.2 %	42.97 %	-26.35 %	-33.6 %	-24.95 %

LITS's 5 Years Annual ROA >> Back to LITS Management Effectiveness >> Compare LITS ROA to its Competitors

More Return On Assets Ratios
LITS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LITS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LITS's Competitors
Subscribers only: Roa for Lite Strategy Inc 's Suppliers
Subscribers only: Return On Assets for LITS's Customers

You may also want to know
LITS's Roi	LITS's Inventory Turnover Ratio	LITS's Growth Rates	LITS's Dividend Comparisons
	LITS's Profitability Ratios	LITS's Asset Turnover Ratio	LITS's Dividend Growth
LITS's Roe	LITS's Valuation Ratios	LITS's Financial Strength Ratios	LITS's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:13:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.